Table 1. Modulation of apoptosis genes in LNCaP treated with enzalutamide or abiraterone.
| Gene | Name | Function | Enzalutamide | Abiraterone |
|---|---|---|---|---|
| CASP1 | Caspase 1 | Proapoptosis | −2.17 | −4.05 |
| CD27 | CD27 molecule | Proapoptosis | −2.26 | −3.50 |
| HRK | Harakiri, BCL-2 interacting protein | Proapoptosis | −2.86 | −8.57 |
| CASP8 | Caspase 8 | Proapoptosis | −2.96 | −2.25 |
| CASP5 | Caspase 5 | Proapoptosis | −3.50 | −4.22 |
| TNFSF8 | Tumor necrosis factor (ligand) super family, member 8 | Proapoptosis | −3.50 | −7.51 |
| TNFRSF25 (DR3) | Tumor necrosis factor receptor super family, member 25 | Proapoptosis | −3.70 | −7.41 |
| DAPK1 | Death-associated protein kinase 1 | Proapoptosis | −6.53 | −13.73 |
| NAIP | NLR family, apoptosis inhibitory protein | Antiapoptosis | −13.90 | −4.72 |
LNCaP (ARPOS) prostate tumor cells were treated with vehicle (DMSO) or 10 μM enzalutamide or abiraterone for 48 hours. Cells were harvested, RNA was extracted and apoptosis array was performed as per the manufacturer's instructions. Nine genes were modulated more than 2-fold by either enzalutamide or abiraterone treatment.